{"id":"NCT01191801","sponsor":"Sunesis Pharmaceuticals","briefTitle":"Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML","officialTitle":"A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12-17","primaryCompletion":"2014-09-26","completion":"2017-03-01","firstPosted":"2010-08-31","resultsPosted":"2017-05-09","lastUpdate":"2018-08-22"},"enrollment":711,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Myeloid Leukemia"],"interventions":[{"type":"DRUG","name":"vosaroxin + cytarabine","otherNames":[]},{"type":"DRUG","name":"placebo + cytarabine","otherNames":["control"]}],"arms":[{"label":"Group A: vosaroxin + cytarabine","type":"EXPERIMENTAL"},{"label":"Group B: placebo + cytarabine","type":"PLACEBO_COMPARATOR"}],"summary":"This study compared treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"Up to 5 years or duration of study","effectByArm":[{"arm":"Group A (Vosaroxin/Cytarabine)","deltaMin":7.5,"sd":null},{"arm":"Group B (Placebo/Cytarabine)","deltaMin":6.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0305"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":124,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Hungary","Italy","New Zealand","Poland","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["26234174"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":197,"n":355},"commonTop":["Nausea","Diarrhoea","Constipation","Hypokalaemia","Febrile neutropenia"]}}